This website uses cookies. By continuing you are agreeing to our privacy policy.

Sharon Pine, Ph.D.

Headshot of Pine
Rutgers, The State University of New Jersey-RBHS-CINJ
Funded by LUNG FORCE
Treating PI3 kinase-mutant NSCLC

Lung cancer is responsible for 25 percent of deaths caused by any cancer in the US. Most patients with lung cancer are diagnosed after the cancer has already spread and, unfortunately, the options for therapy are very few. Some patients with lung adenocarcinoma are eligible for therapy that targets the mutation in their tumor. However, there are still no targeted therapies available for most patients with lung squamous cell carcinoma. Our proposal addresses this problem. We propose to test a novel way to treat squamous cell carcinomas that have a mutation in the gene called PIK3CA. A mutation in PIK3CA is believed to be the "driver" of the tumor. We propose pre-clinical pilot studies to examine a new treatment options for these patients. Our long-term goal is to make targeted therapy a reality for all lung cancer patients. We believe our proposed work will bring us closer to that goal and will ultimately improve survival for patients with lung cancer.

Red button with telephone
Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
Red button of two hand prints
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

Button of turquoise LUNG FORCE swirl
What is LUNG FORCE?

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.